NCT01045096View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Gastroesophageal Reflux
Interventions
DRUG

Dexlansoprazole

Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.

DRUG

Dexlansoprazole

Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days

DRUG

Dexlansoprazole

Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days

Trial Locations (4)

Unknown

Anaheim

Miami Garden

Kansas City

Cincinnati

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY